Treatments for newly diagnosed advanced ovarian cancer: Analysis of survival data and cost-effectiveness evaluation

Anti-Cancer Drugs

Volumn 9, Issue 6, 1998, Pages 491-502

  Messori, Andrea ^a   Trippoli, Sabrina ^a   Becagli, Paola ^a   Tendi, Enrico ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Autologous transplantation; Cisplatin; High dose chemotherapy; Ovarian cancer; Paclitaxel

Indexed keywords

ALTRETAMINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; PACLITAXEL; PLATINUM;

AREA UNDER THE CURVE; ARTICLE; AUTOTRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; DRUG MEGADOSE; DRUG SCREENING; DRUG SENSITIVITY; FEMALE; HUMAN; MULTIMODALITY CANCER THERAPY; OVARY CANCER; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL;

EID: 0031869532     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Runowicz CD, Fields AL, Goldberg GL. Promising new therapies in the treatment of advanced ovarian cancer. Cancer 1995; 76: 2028-33.
2. Baker TR, Piver MS, Hempling RE. Long term survival by cytoreductive surgery to less than 1 cm, induction weekly cisplatin and monthly cisplatin, doxorubicin, and cyclophosphamide therapy in advanced ovarian adenocarcinoma. Cancer 1994; 74: 656-63.
3. Davidson NG, Khanna S, Kirwan P, Bircumshaw D. Advanced ovarian cancer: long-term results following chemotherapy and second-look laparotomy. Gynecol Oncol 1990; 39: 295-9.
4. Del Campo JM, Felip E, Rubio D, Vidal R, Bermejo B. Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment. Gynecol Oncol 1994; 53: 27-32.
5. Hainsworth JD, Grosh WW, Burnett LS, Jones HW. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration. Ann Intern Med 1988; 108: 165-70.
6. Harding M, Milsted R, Hole D, Cordiner J, Barr W. Long term results of cyclophosphamide, adriamycin and platinum chemotherapy in advanced epithelial ovarian cancer. Ann Oncol 1991; 2: 231-3.
7. Hoskins PJ, O'Reilly SE, Swenerton KD, Spinelli Jjm Fairey RN, Benedet JL. Ten-year outcome of patients with advanced epithelial ovarian carcinoma treated with cisplatin-based multimodality therapy. J Clin Oncol 1992; 10: 1561-8.
8. Louie KG, Ozols RF, Myers CE, Ostchega Y, Jenkins J. Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma. J Clin Oncol 1986; 4: 1579-85.
9. Neijt JP, ten Bokkel Huinink WW, van der Burg ME. Combination chemotherapy with or without hexamethylmelamine in alkylating-agent resistant ovarian carcinoma. Cancer 1984; 53: 1467-72.
10. Neijt JP, ten Bokkel Huinink WW, van der Burg ME. Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma. Lancet 1984; ii: 594-600.
11. Neijt JP, ten Bokkel Huinink WW, van der Burg ME. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. J Clin Oncol 1987; 5: 1157-68.
12. Neijt JP, ten Bokkel Huinink WW, van der Burg ME. Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer 1991; 27: 1367-72.
13. Omura GA, Brady MF, Homesley HD, Yordan E, Major FJ. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 1991; 9: 1138-50.
14. Taylor AE, Wiltshaw E, Gore ME, Fryatt I, Fisher C. Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer. J Clin Oncol 1994; 12: 2066-70.
15. Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Br Med J 1991; 303: 884-93.
16. ten Bokkel Huinink WW, van Warmerdam LJ, Helmerhorst TJ, Schaefers MC, Beijnen JH, Rodenhuis S. Phase II study of the combination carboplatin and paclitaxel in patients with ovarian cancer. Ann Oncol 1997; 8: 351-4.
17. Wadler S, Yeap B, Vogl S, Carbone P. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results - Eastern Cooperative Oncology Group Study E2878. Cancer 1996; 77: 733-42.
18. Warwick J, Kehoe S, Earl H, Luesley D, Redman. Long-term follow-up of patients with advanced ovarian cancer treated in randomised clinical trials. Br J Cancer 1995; 72: 1513-7.
19. Wils JA. Long-term follow-up of patients with advanced ovarian carcinoma treated with debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide. Gynecologic Oncology Group of the Comprehensive Cancer Center. Oncology 1990; 47: 115-20.
20. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY. Cyclophospamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
21. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12: 2654-66.
22. Legros M, Dauplat J, Fleury J, et al. High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long-term results. J Clin Oncol 1997; 15: 1302-8.
23. Stiff PJ, Bayer R, Kerger C, et al. High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer a multivariate analysis of survival for 100 consecutively treated patients. J Clin Oncol 1997; 15: 1309-17.
24. Viens P, Maraninchi D, Legros M, et al. High dose melphalan and autologous marrow rescue in advanced epithelial ovarian carcinomas: a retrospective analysis of 35 patients treated in France. Bone Marrow Transplant 1990; 5: 227-33.
25. Benedetti-Panici P, Greggi S, Scambia G, et al. Very high-dose chemotherapy with autologous peripheral stem cell support in advanced ovarian cancer. Eur J Cancer 1995; 31A: 1987-92.
26. Menichella G, Pierelli L, Foddai ML, et al. Autologous blood stem cell harvesting and transplantation in patients with advanced ovarian cancer. Br J Haematol 1991; 79: 444-50.
27. Shpall EJ, Clarke-Pearson D, Soper JT, et al. High-dose alkylating agent chemotherapy with autologous hone marrow support in patients with stage III/IV epithelial ovarian cancer. Gynecol Oncol 1990; 38: 386-91.
28. Messori A, Trippoli S, Becagli P, Tendi E. Pharmacoeconomic profile of paclitaxel as first-line treatment for patients with advanced ovarian cancer: a lifetime cost-effectiveness analysis. Cancer 1996; 78: 2366-73.
29. Messori A, Becagli P, Trippoli S, Tendi E. A retrospective cost-effectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanoma. Eur J Cancer 1997; 33: 1373-9.
30. Messori A, Bonistalli L, Costantini M, Alterini R. Cost-effectiveness of autologous bone marrow transplantation in patients with relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant 1997; 19: 275-81.
31. Messori A, Becagli P, Trippoli S, Tendi E. Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide+methotrexate+fluorouracil in patients with node-positive breast cancer. Eur J Clin Pharmacol 1996; 51: 111-6.
32. Messori A. Survival curve fitting using the Gompertz function: a methodology for conducting cost-effectiveness analyses on mortality data. Comput Meth Progr Biomed 1997; 52: 157-64.
33. Simes RJ. Confronting publication bias: a cohort design for meta-analysis. Stat Med 1987; 6: 11-29.
34. de Arriba F, Heras I, del Carmen Garcia M, et al. Economic costs of autotransplantation of hematopoietic progenitors. Med Clin (Barc) 1996; 106: 329-32.
35. Souetre E, Qing W, Penelaud PF. Economic analysis of the use of recombinant human granulocyte colony stimulating factor in autologous bone marrow transplantation. Eur J Cancer 1996; 32A: 1162-5.
36. Henon P, Donatini B, Eisenmann JC, Becker M, Beck-Wirth G. Comparative survival, quality of life and cost-effectiveness of intensive therapy with autologous blood cell transplantation or concentional chemotherapy in multiple myeloma. Bone Marrow Transplant 1995; 16: 19-25.
37. Ager S, Scott MA, Mahendra P, et al. Peripheral blood stem cell transplantation after high-dose therapy in patients with malignant lymphoma: a retrospective comparison with autologous bone marrow transplantation. Bone Marrow Transplant 1995; 16: 79-83.
38. Uyl-de Groot CA, Okhuijsen SY, Hagenbeek A. et al. Costs of introducing autologous BMT in the treatment of lymphoma and acute leukaemia in The Netherlands. Bone Marrow Transplant 1995; 15: 605-10.
39. Uyl-de Groot CA, Hagenbeek A, Verdonck LF, Lowenberg B, Rutten FFH. Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate and high-grade malignant non-Hodgkin's lymphoma (NHL). Bone Marrow Transplant 1995; 16: 463-70.
40. Schulman KA. Economics of bone marrow transplantation. J Clin Oncol 1996; 14; 1409-10.
41. Smith TJ, Hillner BE, Schmitz N, et al. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 5-10.
42. Bennett CL, Armitage JL, Armitage GO, et al. Cost of care and outcomes for high-dose therapy and autologous transplantation for lymphoid malignancies: results from the University of Nebraska 1987 through 1991. J Clin Oncol 1995; 13: 969-73.
43. Lawless GD. Cost-effectiveness of autologous bone marrow transplantation. Am J Health-Syst Pharm 1995; 52(suppl 4): S11-4.
44. Hillner BE, Smith TJ, Desch CE. Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer. Estimates using decision analysis awaiting clinical trial results. J Am Med Ass 1992; 267: 2055-61.
45. Krause KK. Variations in insurance coverage for autologous bone marrow transplantation for breast cancer (Letter). N Engl J Med 1994; 331: 329.
46. Peters WP, Ross M, Vredenburgh JJ, et al. The use of intensive clinic support to permit outpatient autologous bone marrow transplantation for breast cancer. Semin Oncol 1994; 21: 25-31.
47. Rio B, Marjanovic Z, Belhocine R. Difference in costs of autologous transplantation of peripheral and bone marrow hematopoietic stem cells. A retrospective analysis over 1 year of transplantation in lymphoma. Hodgkin's disease and myeloma in a Center. Ann Med Intern (Paris) 1996; 147: 313-9.
48. McGuire W, Neugut AI, Arikian S, Doyle J, Dezii CM. Analysis of the cost-effectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer. J Clin Oncol 1997; 15: 640-5.
49. Elit LM, Gafni A, Levine MN. Economic and policy implications of adopting paclitaxel as first-line therapy for advanced ovarian cancer: an Ontario perspective. J Clin Oncol 1997; 15: 623-39.
50. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. J Am Med Ass 1996; 276: 1253-8.
51. Messori A, Cecchi M, Becagli P, Trippoli S. Phormaco-economic profile of paclitaxel as first-line treatment for patients with advanced ovarian cancer: a lifetime cost-effectiveness analysis (Letter). Cancer 1997; 79: 2264-5.
52. Messori A, Bonistalli L, Costantini M, Trallori G, Tendi E. Cost-effectiveness of adjuvant intraportal chemotherapy in colorectal cancer. J Clin Gastroenterol 1996; 23: 269-74.
53. Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995; 332: 1418-24.
54. Hillner BK, Kirkwood JM, Atkins MB, Johnson ER, Smith TJ. Economic analysis of adjuvant Interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684. J Clin Oncol 1997; 15: 2351-8.
55. Messori A, Costantini M, Bonistalli L, Alterini R. Second bone marrow transplantation in non-Hodgkin's lymphoma. J Clin Oncol 1998; 16: 804-6.
56. Barton MB, Gebski V, Manderson C, Langlands AO. Radiation therapy: are we getting value for money? Clin Oncol 1995; 7: 287-92.
57. Fine HA, Dear KBG, Loeffler JS, Black PML, Canellos GP. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993; 71: 2585-92.